Elif AYDINGÖZ, Mehmet Ali NAZLI, Mert BAL
European Journal of Breast Health - 2026;22(2):218-225
Objective: To evaluate the feasibility of using deep learning models applied to digital breast tomosynthesis (DBT) images for non-invasive prediction of breast cancer biomarkers, including estrogen receptor (ER), progesterone receptor (PR), human epithelial growth factor receptor 2 (HER2), Ki-67 proliferation index, and triple-negative breast cancer (TNBC). Materials and Methods: In this retrospective study, patients with histopathologically-confirmed, invasive breast cancer were included. Furthermore, all included patients had complete, immunohistochemically-assessed biomarker data available. For each case, a representative DBT slice showing the tumor was selected and preprocessed using histogram equalization. Two pretrained convolutional neural networks (VGG19 and ResNet50) were fine-tuned for binary classification of each biomarker. Model performance was evaluated using accuracy, area under the curve (AUC), F1 score, and Matthews correlation coefficient. Results: The study sample included 43 anonymized female patients. Deep learning models achieved strong predictive performance for ER (AUC = 0.81) and TNBC (AUC = 0.93). HER2 (AUC = 0.74) and Ki-67 index (AUC = 0.70) were predicted with moderate accuracy. PR results varied, with VGG19 reaching AUC = 0.76 while ResNet50 performed poorly (AUC = 0.24). Conclusion: Deep learning models applied to DBT images enabled non-invasive prediction of some key breast cancer biomarkers, especially ER status and TNBC type. This approach may function as a virtual biopsy to complement histopathology, guide biopsy targeting, and support treatment planning. Although preliminary, the findings highlight the potential of artificial intelligence-enhanced DBT assessment and warrant validation in larger, multi-center prospective studies.
